Department of Ophthalmology, Istanbul Research and Education Hospital, Istanbul, Turkey.
Department of Ophthalmology, Bolu Abant Izzet Baysal University, Izzet Baysal Training and Research Hospital, Bolu, Turkey.
Int Ophthalmol. 2021 Apr;41(4):1479-1485. doi: 10.1007/s10792-021-01708-1. Epub 2021 Jan 23.
To evaluate the clinical effect of topical cyclosporine A (CsA) (0.05%) on dry eye patients with Sjogren's syndrome (SS) and non-Sjogren's syndrome (NSS).
This retrospective comparative study includes the dry eye (DE) patients who were treated with topical CsA. DE patients were divided into two groups as follows: DE with Sjogren's syndrome (DE-SS) and DE with Non-Sjogren's syndrome (DE-NSS). Dry eye parameters were recorded at baseline and each visit.
Schirmer's test 1 scores were 2.7 ± 0.5 mm at baseline and 3.5 ± 0.7 mm at 12th month in DE-SS, 2.9 ± 0.7 mm at baseline and 9.5 ± 0.7 mm in DE-NSS groups at 12th month. Mean ST score was higher in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (both p = 0.001). Tear break-up time score showed a significant improvement in DE-NSS group, and it was lower in DE-NSS group than DE-SS group group at sixth and 12th months of the treatment (p = 0.044 and 0.027, respectively). Mean OSDI score was lower in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (p = 0.030 and 0.032, respectively).
Topical CsA seems to be more effective in the treatment of the DE-NSS.
评估局部环孢素 A（CsA）（0.05%）治疗干燥综合征（SS）和非干燥综合征（NSS）患者干眼症的临床疗效。
本回顾性对照研究包括接受局部 CsA 治疗的干眼症（DE）患者。DE 患者分为以下两组：干燥综合征相关干眼症（DE-SS）和非干燥综合征相关干眼症（DE-NSS）。在基线和每次就诊时记录干眼参数。
SS 组 Schirmer 试验 1 评分从基线的 2.7±0.5mm 增加到 12 个月时的 3.5±0.7mm，NSS 组从基线的 2.9±0.7mm 增加到 12 个月时的 9.5±0.7mm。在治疗的第 6 和 12 个月，NSS 组的平均 ST 评分均高于 SS 组（均 p=0.001）。泪膜破裂时间评分在 NSS 组中显著改善，且在治疗的第 6 和 12 个月时均低于 SS 组（分别为 p=0.044 和 0.027）。NSS 组的平均 OSDI 评分低于 SS 组，在治疗的第 6 和 12 个月时差异有统计学意义（分别为 p=0.030 和 0.032）。
局部 CsA 似乎对 NSS 相关的 DE 治疗更有效。
